Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial

Amy S. Paller(Northwestern University), Brad Shumel(Regeneron (United States)), Melinda Gooderham(Queen's University), Jamie Weisman(Institute for Advanced Medical Research), John T. O’Malley(Sanofi (United States)), Michael J. Cork(University of Sheffield), David M. Weinreich(Regeneron (United States)), Peter D. Arkwright(University of Manchester), Bethany Beazley(Regeneron (United States)), Megan Hardin(Sanofi (United States)), Mark Boguniewicz(University of Colorado Denver), Andreas Wollenberg(Vrije Universiteit Brussel), Mohamed Kamal(Regeneron (United States)), Neil M.H. Graham(Regeneron (United States)), Lisa A. Beck(University of Rochester Medical Center), George D. Yancopoulos(Regeneron (United States)), Ashish Bansal(Regeneron (United States)), Diamant Thaçi(University of Lübeck), Elaine C. Siegfried(Saint Louis University), Lawrence Sher(Peninsula Research), Xian Sun(Regeneron (United States)), Marcella Ruddy(Regeneron (United States)), John D. Davis(Regeneron (United States)), Faisal A. Khokhar(Regeneron (United States)), Naimish Patel(Sanofi (United States))
Journal of the American Academy of Dermatology
June 20, 2020
Cited by 385


Related Papers